Non-small cell lung carcinoma, Hepatocellular carcinoma, Solid tumor/s
CHRSCoherus BioSciences Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Toripalimab +/- CHS-006 (anti-TIGIT) (anti-PD-1) in Non-small cell lung carcinoma, Hepatocellular carcinoma, Solid tumor/s. The expected timing is based on the latest available company guidance and may change.
Joint development w/ Junshi Biosci. Initiated in Q2 2023. 8/2/23- Ongoing enrollment. 11/06/25:- PR No update. 03/09/26:- PR No update. 05/11/26:- PR No update. 08/05/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.